Related
AstraZeneca Drug Regimen Improves PFS in First-Line Rare Blood Cancer
Rare Daily Staff Positive high-level results from an interim analysis of the ECHO phase 3 trial showed […]
Read moreSoleno Raises $138 Million in Public Offering to Advance Treatment for Prader-Willi
Rare Daily Staff Rare disease focused biotech Soleno Therapeutics raised $138 million in an underwritten public offering […]
Read moreLatus Bio Launches with $54 Million to Deliver Gene Therapies Directly to the Brain
Rare Daily Staff Latus Bio, a company developing improved gene therapies that target central nervous system disorders, […]
Read moreAI Used to Identify Undiagnosed Patients with Immune Disorder through EHRs
Rare Daily Staff Researchers were able to identify people suspected of having an undiagnosed, rare immunodeficency through […]
Read moreFDA Grants Fast Track to Amolyt’s Experimental Hypoparathyroidism Candidate
Rare Daily Staff The U.S. Food and Drug Administration granted Fast Track designation to Amolyt Pharma’s lead […]
Read moreModerna and Metagenomi End Next-Generation In Vivo Gene Editing Collaboration
Rare Daily Staff Moderna and Metagenomi have agreed to terminate their collaboration to develop next-generation, in vivo […]
Read moreUsing Directed Evolution to Develop New Vectors for Genetic Medicines
Much of the challenge of developing genetic medicines lies in having the right vector to deliver the […]
Read moreAtsena Reports Positive Data from First Cohort of Trial Evaluating Gene Therapy for XLRS
Rare Daily Staff Atsena Therapeutics reported positive preliminary data from the first cohort of the ongoing LIGHTHOUSE […]
Read moreCreyon and Cajal Enter Partnership to Develop ASOs for Neurodegenerative Diseases
Rare Daily Staff Creyon Bio and Cajal Neuroscience have entered a partnership to develop novel antisense oligonucleotide […]
Read more